MGC Pharmaceuticals has completed a successful in-vitro preclinical research study into the use of cannabinoids to treat aggressive brain cancer glioblastoma.
Conducted between 2019 and 2022, the study initially used a formulation including THC, later replaced with cannabigerol (CBG).
Biopsy samples taken from 18 patients and more than 5,800 cell tests were used to determine the most effective concentrations and ratios of CBD and CBG in the treatment formulation.
The results demonstrated the efficacy of cannabinoids in the treatment of glioblastoma and the most effective CBD:CBG ratio in inhibiting tumour viability.
As well as killing tumours and stem cells, tests showed the CBD/CBD formulation’s efficacy was not enhanced by the addition of a widely used chemotherapy treatment which has been linked to adverse events.
Managing director Roby Zomer said the results were “enormously exciting” for the treatment of fatal cancerous tumours.
He added: “MGC Pharma’s research has demonstrated the effect of naturally derived cannabinoid products on stage four brain tumours without the use of toxic chemotherapy components.
“We are proud of the work achieved thus far and are looking forward to advancing our proprietary formulation to the next stage of clinical trials.”